Translate Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, announced its participation in two upcoming investor conferences. John Schroer, CFO, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. ET. CEO Ronald Renaud will engage in a fireside chat at the Evercore ISI HealthCONx Conference on December 2, 2020, at 2:15 p.m. ET. Live webcasts of these presentations will be available on the company's website, with replays archived for 30 days.

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

• Jefferies Virtual London Healthcare Conference: John Schroer, chief financial officer, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 a.m. ET.
• Evercore ISI HealthCONx Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 2:15 p.m. ET.

A live webcast of the sessions will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Contacts for Translate Bio
Investors  Teri Dahlman tdahlman@translate.bio 617-817-8655	Media Maura Gavaghan mgavaghan@translate.bio 617-233-1154

FAQ

What is the date and time of Translate Bio's presentation at the Jefferies Virtual London Healthcare Conference?

Translate Bio will present on November 18, 2020, at 7:55 a.m. ET.

Who is presenting at the Evercore ISI HealthCONx Conference for Translate Bio?

Ronald Renaud, CEO of Translate Bio, will participate in a fireside chat.

How can I access the webcasts of the Translate Bio investor presentations?

The webcasts will be accessible through the 'Events and Presentations' page on Translate Bio's website.

What is the focus of Translate Bio's mRNA therapeutics development?

Translate Bio focuses on developing medicines for diseases caused by protein dysfunction and for preventing infectious diseases.

What is the lead candidate for Translate Bio in the pulmonary disease area?

Translate Bio's lead candidate is an inhaled treatment for cystic fibrosis, currently in Phase 1/2 clinical trials.